

# Manuel Menendez-Gonzalez

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4893806/publications.pdf>

Version: 2024-02-01

118  
papers

3,717  
citations

172457  
29  
h-index

168389  
53  
g-index

136  
all docs

136  
docs citations

136  
times ranked

5665  
citing authors

#	ARTICLE	IF	CITATIONS
1	New insights into the genetic etiology of Alzheimer's disease and related dementias. <i>Nature Genetics</i> , 2022, 54, 412-436.	21.4	700
2	Dopaminergic reward system: a short integrative review. <i>International Archive of Medicine</i> , 2010, 3, 24.	1.2	293
3	Down syndrome, Alzheimer's disease and seizures. <i>Brain and Development</i> , 2005, 27, 246-252.	1.1	157
4	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021, 12, 3417.	12.8	140
5	Profile of microRNAs in the plasma of Parkinson's disease patients and healthy controls. <i>Journal of Neurology</i> , 2013, 260, 1420-1422.	3.6	132
6	Genome-wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project. <i>Alzheimer's and Dementia</i> , 2019, 15, 1333-1347.	0.8	111
7	Mitochondria function associated genes contribute to Parkinson's Disease risk and later age at onset. <i>Npj Parkinson's Disease</i> , 2019, 5, 8.	5.3	95
8	<i>SPG7</i> mutational screening in spastic paraplegia patients supports a dominant effect for some mutations and a pathogenic role for p.A510V. <i>Clinical Genetics</i> , 2013, 83, 257-262.	2.0	94
9	Action naming is impaired in Parkinson disease patients. <i>Neuropsychologia</i> , 2009, 47, 3271-3274.	1.6	83
10	Moving beyond neurons: the role of cell type-specific gene regulation in Parkinson's disease heritability. <i>Npj Parkinson's Disease</i> , 2019, 5, 6.	5.3	83
11	Non-motor symptoms burden, mood, and gait problems are the most significant factors contributing to a poor quality of life in non-demented Parkinson's disease patients: Results from the COPPADIS Study Cohort. <i>Parkinsonism and Related Disorders</i> , 2019, 66, 151-157.	2.2	71
12	COPPADIS-2015 (COhort of Patients with PARKinson's Disease in Spain, 2015), a global "clinical evaluations, serum biomarkers, genetic studies and neuroimaging" prospective, multicenter, non-interventional, long-term study on Parkinson's disease progression. <i>BMC Neurology</i> , 2016, 16, 26.	1.8	66
13	MiRNA Profile in the Substantia Nigra of Parkinson's Disease and Healthy Subjects. <i>Journal of Molecular Neuroscience</i> , 2014, 54, 830-836.	2.3	58
14	Penetrance of Parkinson's Disease in <i>LRRK2</i> p.G2019S Carriers Is Modified by a Polygenic Risk Score. <i>Movement Disorders</i> , 2020, 35, 774-780.	3.9	57
15	The mirror neuron system in post-stroke rehabilitation. <i>International Archive of Medicine</i> , 2013, 6, 41.	1.2	56
16	Immunotherapy for Alzheimer's Disease: Rational Basis in Ongoing Clinical Trials. <i>Current Pharmaceutical Design</i> , 2011, 17, 508-520.	1.9	50
17	A Search for SNCA 3' UTR Variants Identified SNP rs356165 as a Determinant of Disease Risk and Onset Age in Parkinson's Disease. <i>Journal of Molecular Neuroscience</i> , 2012, 47, 425-430.	2.3	49
18	Lipid-specific immunoglobulin M bands in cerebrospinal fluid are associated with a reduced risk of developing progressive multifocal leukoencephalopathy during treatment with natalizumab. <i>Annals of Neurology</i> , 2015, 77, 447-457.	5.3	48

#	ARTICLE	IF	CITATIONS
19	The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population-Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. <i>Movement Disorders</i> , 2019, 34, 1851-1863.	3.9	47
20	FGF20 rs12720208 SNP and microRNA-433 variation: No association with Parkinson's disease in Spanish patients. <i>Neuroscience Letters</i> , 2010, 479, 22-25.	2.1	46
21	A new de novo Notch3 mutation causing CADASIL. <i>European Journal of Neurology</i> , 2006, 13, 628-631.	3.3	45
22	APP Processing and the APP-KPI Domain Involvement in the Amyloid Cascade. <i>Neurodegenerative Diseases</i> , 2005, 2, 277-283.	1.4	43
23	Generalized Models for the Classification of Abnormal Movements in Daily Life and its Applicability to Epilepsy Convulsion Recognition. <i>International Journal of Neural Systems</i> , 2016, 26, 1650037.	5.2	42
24	Exacerbation of Lewy bodies dementia due to memantine. <i>Journal of Alzheimer's Disease</i> , 2005, 8, 289-291.	2.6	40
25	Prevalence of Depression and Anxiety in Parkinson Disease and Impact on Quality of Life: A Community-Based Study in Spain. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2020, 33, 207-213.	2.3	39
26	Cognitive impairment in Parkinson's disease without dementia. <i>Movement Disorders</i> , 2010, 25, 2136-2141.	3.9	36
27	Role for ATXN1, ATXN2, and HTT intermediate repeats in frontotemporal dementia and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020, 87, 139.e1-139.e7.	3.1	35
28	Analysis of the <i>MicroRNA-133</i> and <i>PITX3</i> genes in Parkinson's disease. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2010, 153B, 1234-1239.	1.7	33
29	Late-onset Alzheimer's disease is associated with mitochondrial DNA 7028C/haplogroup H and D310 poly-C tract heteroplasmy. <i>Neurogenetics</i> , 2011, 12, 345-346.	1.4	33
30	Comparison of Extracellular and Intracellular Blood Compartments Highlights Redox Alterations in Alzheimer's and Mild Cognitive Impairment Patients. <i>Current Alzheimer Research</i> , 2016, 14, 112-122.	1.4	33
31	COPPADIS 2015 Cohort of Patients with Parkinson's Disease in Tj ETQq1 1 0.784314 rgBT 1000 subjects included. Results from the baseline evaluation. <i>European Journal of Neurology</i> , 2019, 26, 1399-1407.	3.3	32
32	Diagnoses behind patients with hard-to-classify tremor and normal DaT-SPECT: a clinical follow up study. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 56.	3.4	31
33	Alpha-synuclein transcript isoforms in three different brain regions from Parkinson's disease and healthy subjects in relation to the SNCA rs356165/rs11931074 polymorphisms. <i>Neuroscience Letters</i> , 2014, 562, 45-49.	2.1	30
34	Semantic Markers in the Diagnosis of Neurodegenerative Dementias. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 28, 267-274.	1.5	29
35	Pathological and clinical heterogeneity of presenilin 1 gene mutations. <i>Journal of Alzheimer's Disease</i> , 2004, 6, 475-482.	2.6	28
36	Transient Global Amnesia. <i>Archives of Neurology</i> , 2006, 63, 1334.	4.5	28

#	ARTICLE	IF	CITATIONS
37	Epilepsia mioclónica en el síndrome de Down y en la enfermedad de Alzheimer. Neurología, 2017, 32, 69-73.	0.7	23
38	Routine lumbar puncture for the early diagnosis of Alzheimer's disease. Is it safe?. Frontiers in Aging Neuroscience, 2014, 6, 65.	3.4	21
39	SNCA and mTOR Pathway Single Nucleotide Polymorphisms Interact to Modulate the Age at Onset of Parkinson's Disease. Movement Disorders, 2019, 34, 1333-1344.	3.9	21
40	HTT gene intermediate alleles in neurodegeneration: evidence for association with Alzheimer's disease. Neurobiology of Aging, 2019, 76, 215.e9-215.e14.	3.1	21
41	Orquestic regulation of neurotransmitters on reward-seeking behavior. International Archive of Medicine, 2014, 7, 29.	1.2	20
42	Targeting Beta-Amyloid at the CSF: A New Therapeutic Strategy in Alzheimer's Disease. Frontiers in Aging Neuroscience, 2018, 10, 100.	3.4	20
43	Value of Measuring Plasmatic Levels of Neurosin in the Diagnosis of Alzheimer's Disease. Journal of Alzheimer's Disease, 2008, 14, 59-67.	2.6	19
44	Time perception impairs sensory-motor integration in Parkinson's disease. International Archive of Medicine, 2013, 6, 39.	1.2	19
45	Cerebral Gas Embolism Caused by Pleural Fibrinolytic Treatment. Stroke, 2007, 38, 2602-2604.	2.0	18
46	Clinical Implication of Meissner's Corpuscles. CNS and Neurological Disorders - Drug Targets, 2012, 11, 856-868.	1.4	18
47	Vasomotor Reactivity Is Similarly Impaired in Patients with Alzheimer's Disease and Patients with Amyloid Hemorrhage. , 2011, 21, e83-e85.		17
48	Myocyte enhancing factor-2A in Alzheimer's disease: Genetic analysis and association with MEF2A-polymorphisms. Neuroscience Letters, 2007, 411, 47-51.	2.1	16
49	Lack of association between protocadherin 11-X/Y (PCDH11X and PCDH11Y) polymorphisms and late onset Alzheimer's disease. Brain Research, 2011, 1383, 252-256.	2.2	16
50	MTA index: a simple 2D-method for assessing atrophy of the medial temporal lobe using clinically available neuroimaging. Frontiers in Aging Neuroscience, 2014, 6, 23.	3.4	16
51	LRP10 in $\alpha$ -synucleinopathies. Lancet Neurology, The, 2018, 17, 1032.	10.2	15
52	Albumin Exchange in Alzheimer's Disease: Might CSF Be an Alternative Route to Plasma?. Frontiers in Neurology, 2019, 10, 1036.	2.4	15
53	Co-Enzyme Q10 to Treat Neurological Disorders: Basic Mechanisms, Clinical Outcomes, and Future Research Direction. CNS and Neurological Disorders - Drug Targets, 2013, 12, 641-664.	1.4	15
54	The screening of the 3'UTR sequence of LRRK2 identified an association between the rs66737902 polymorphism and Parkinson's disease. Journal of Human Genetics, 2014, 59, 346-348.	2.3	14

#	ARTICLE	IF	CITATIONS
55	Perrault syndrome with neurological features in a compound heterozygote for two TWNK mutations: overlap of TWNK-related recessive disorders. <i>Journal of Translational Medicine</i> , 2019, 17, 290.	4.4	14
56	Clearing Extracellular Alpha-Synuclein from Cerebrospinal Fluid: A New Therapeutic Strategy in Parkinson's Disease. <i>Brain Sciences</i> , 2018, 8, 52.	2.3	13
57	Magnetic Resonance Techniques Applied to the Diagnosis and Treatment of Parkinson's Disease. <i>Frontiers in Neurology</i> , 2015, 6, 146.	2.4	12
58	Partial trisomy 13q22-qter associated to leukoencephalopathy and late onset generalised epilepsy. <i>International Archive of Medicine</i> , 2008, 1, 5.	1.2	11
59	Mutational Screening of PARKIN Identified a 3' UTR Variant (rs62637702) Associated with Parkinson's Disease. <i>Journal of Molecular Neuroscience</i> , 2013, 50, 264-269.	2.3	11
60	Structural Neuroimaging of the Medial Temporal Lobe in Alzheimer's Disease Clinical Trials. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 581-589.	2.6	11
61	High ultrasensitive serum C-reactive protein may be related to freezing of gait in Parkinson's disease patients. <i>Journal of Neural Transmission</i> , 2019, 126, 1599-1608.	2.8	11
62	Defining the profile of International Archives of Medicine. <i>International Archive of Medicine</i> , 2008, 1, 1.	1.2	10
63	The Sp1/Egr1-tandem Repeat Polymorphism in the 5-Lipoxygenase Gene Promoter is not Associated With Late Onset Alzheimer Disease. <i>Alzheimer Disease and Associated Disorders</i> , 2008, 22, 177-180.	1.3	10
64	Identification of abnormal movements with 3D accelerometer sensors for seizure recognition. <i>Journal of Applied Logic</i> , 2017, 24, 54-61.	1.1	10
65	Manual Planimetry of the Medial Temporal Lobe Versus Automated Volumetry of the Hippocampus in the Diagnosis of Alzheimer's Disease. <i>Cureus</i> , 2016, 8, e544.	0.5	10
66	Functional coupling of sensorimotor and associative areas during a catching ball task: a qEEG coherence study. <i>International Archive of Medicine</i> , 2012, 5, 9.	1.2	9
67	Evidence of Nestin-Positive Cells in the Human Cutaneous Meissner and Pacinian Corpuscles. <i>CNS and Neurological Disorders - Drug Targets</i> , 2012, 11, 869-877.	1.4	9
68	Implantable Systems for Continuous Liquorpheresis and CSF Replacement. <i>Cureus</i> , 2017, 9, e1022.	0.5	9
69	Feasibility of the Medial Temporal lobe Atrophy index (MTAi) and derived methods for measuring atrophy of the medial temporal lobe. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 305.	3.4	8
70	Implications of movement-related cortical potential for understanding neural adaptations in muscle strength tasks. <i>International Archive of Medicine</i> , 2014, 7, 9.	1.2	8
71	The Role of Innate Immune System Receptors in Epilepsy Research. <i>CNS and Neurological Disorders - Drug Targets</i> , 2017, 16, 749-762.	1.4	8
72	Genetic variation in APOE, GRN, and TP53 are phenotype modifiers in frontotemporal dementia. <i>Neurobiology of Aging</i> , 2021, 99, 99.e15-99.e22.	3.1	8

#	ARTICLE	IF	CITATIONS
73	C9orf72, age at onset, and ancestry help discriminate behavioral from language variants in FTL cohorts. <i>Neurology</i> , 2020, 95, e3288-e3302.	1.1	7
74	Patients with Parkinson's Disease Show Alteration in their Visuospatial Abilities and in their Egocentric and Allocentric Spatial Orientation Measured by Card Placing Tests. <i>Journal of Parkinson's Disease</i> , 2020, 10, 1807-1816.	2.8	7
75	Genomic Characterization of Host Factors Related to SARS-CoV-2 Infection in People with Dementia and Control Populations: The GR@ACE/DEGESCO Study. <i>Journal of Personalized Medicine</i> , 2021, 11, 1318.	2.5	7
76	The "Cerebrospinal Fluid Sink Therapeutic Strategy" in Alzheimer's Disease "From Theory to Design of Applied Systems. <i>Biomedicines</i> , 2022, 10, 1509.	3.2	7
77	Plasmatic level of neurosin predicts outcome of mild cognitive impairment. <i>International Archive of Medicine</i> , 2008, 1, 11.	1.2	6
78	Isolation and characterization of entomopathogenic bacteria from soil samples from the western region of Cuba. <i>Journal of Vector Ecology</i> , 2013, 38, 46-52.	1.0	6
79	The many questions on the use of biomarkers for neurodegenerative diseases in clinical practice. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 45.	3.4	6
80	The yearly rate of Relative Thalamic Atrophy (yrRTA): a simple 2D/3D method for estimating deep gray matter atrophy in Multiple Sclerosis. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 219.	3.4	6
81	Frontotemporal Lobe Degeneration as Origin of Scans Without Evidence of Dopaminergic Deficit. <i>Frontiers in Neurology</i> , 2018, 9, 335.	2.4	6
82	Sodium chloride regulates Extracellular Regulated Kinase 1/2 in different tumor cell lines. <i>Molecular and Cellular Biochemistry</i> , 2006, 293, 93-101.	3.1	5
83	Panic attack triggering myocardial ischemia documented by myocardial perfusion imaging study. A case report. <i>International Archive of Medicine</i> , 2012, 5, 24.	1.2	5
84	Atlas of Biomarkers for Alzheimer's Disease. , 2014, , .		5
85	Fuzzy rule learning with ACO in epilepsy crisis identification. , 2015, , .		5
86	Neuropsychological Test Performance in Parkinsonism Without Dopaminergic Deficiency on [123I]-FP-CIT SPECT Imaging. <i>Journal of the International Neuropsychological Society</i> , 2018, 24, 646-651.	1.8	5
87	Effects of Methylphenidate on performance of a practical pistol shooting task: a quantitative electroencephalography (qEEG) study. <i>International Archive of Medicine</i> , 2011, 4, 6.	1.2	4
88	Amyloid Precursor Protein Gene (APP) Variation in Late-Onset Alzheimer's Disease. <i>Journal of Molecular Neuroscience</i> , 2011, 45, 5-9.	2.3	4
89	Biomarkers in neurodegenerative disorders: translating research into clinical practice. <i>Frontiers in Aging Neuroscience</i> , 2014, 6, 281.	3.4	4
90	Deletion of DNA sequences of using a polymerase chain reaction based approach. <i>Electronic Journal of Biotechnology</i> , 2006, 9, 0-0.	2.2	4

#	ARTICLE	IF	CITATIONS
91	Relation between type of personality and academic performance among Malaysian health sciences students. International Archive of Medicine, 0, , .	1.2	4
92	Mechanical Dilution of Beta-amyloid Peptide and Phosphorylated Tau Protein in Alzheimer's Disease: Too Simple to be True?. Cureus, 2017, 9, e1062.	0.5	4
93	Hypertonicity activates GSK3 $\beta$ in tumor cells. Molecular and Cellular Biochemistry, 2006, 291, 93-100.	3.1	3
94	A series of cases with Huntington-like phenotype and intermediate repeats in HTT. Journal of the Neurological Sciences, 2021, 425, 117452.	0.6	3
95	Indices of Regional Brain Atrophy: Formulae and Nomenclature. Cureus, 2015, 7, e295.	0.5	3
96	Partial motor status epilepticus as a clinical manifestation of carotid stenosis. International Archive of Medicine, 2010, 3, 18.	1.2	2
97	Single neuron electroporation in manipulating and measuring the central nervous system. International Archive of Medicine, 2010, 3, 28.	1.2	2
98	Pre-Clinical Study on the Detection of Simulated Epileptic Seizures. International Journal of Uncertainty, Fuzziness and Knowledge-Based Systems, 2016, 24, 33-46.	1.9	2
99	Postural control modulation during motor imagery tasks: a systematic review. International Archive of Medicine, 0, , .	1.2	2
100	Smoking is associated with age at disease onset in Parkinson's disease. Parkinsonism and Related Disorders, 2022, 97, 79-83.	2.2	2
101	Editorial: Neuropsychology and Neuropsychiatry of Neurodegenerative Disorders. Frontiers in Aging Neuroscience, 2015, 7, 227.	3.4	1
102	Association between naturally occurring anti-amyloid $\beta$ autoantibodies and medial temporal lobe atrophy in Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 96-97.	1.9	1
103	Transient Global Amnesia. Journal of Neurosciences in Rural Practice, 2017, 08, S102-S102.	0.8	1
104	Impact of Depression and Anxiety on Dimensions of Health-Related Quality of Life in Subjects with Parkinson's Disease Enrolled in an Association of Patients. Brain Sciences, 2021, 11, 771.	2.3	1
105	Planimetry of the medial temporal lobe: a feasible method for supporting the diagnosis of Alzheimer's disease in clinical practice. Neurology and Neuroscience, 0, , .	0.0	1
106	Early Diagnosis and Risk of Conversion from Presymptomatic Stages. , 2014, , 1-15.		1
107	Comparing ACO Approaches in Epilepsy Seizures. Lecture Notes in Computer Science, 2016, , 261-272.	1.3	1
108	Performance on Daily Life Activities and Executive Functioning in Parkinson Disease. Topics in Geriatric Rehabilitation, 2020, 36, 252-259.	0.4	1

#	ARTICLE	IF	CITATIONS
109	P1-153: The 2D-MTA is a feasible method for assessing atrophy of the medial temporal lobe in daily clinical practice. , 2015, 11, P403-P403.		0
110	Unrevealing the diagnoses of a sample of cases with hard-to-classify tremor and normal DaT-SPECT. Parkinsonism and Related Disorders, 2016, 22, e129.	2.2	0
111	Volumetry of the olfactory bulbs and tracts in the differential diagnosis of Parkinson's disease from parkinsonisms. Parkinsonism and Related Disorders, 2016, 22, e157.	2.2	0
112	[P3â€™091]: EFFECTIVE ANALYSIS OF GENE EXPRESSION FOR THE DISCOVERY OF BIOMARKERS AND THERAPEUTIC TARGETS FOR ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P968.	0.8	0
113	The Prion-like Properties of Amyloid-beta Peptide and Tau: Is there Any Risk of Transmitting Alzheimer's Disease During Neurosurgical Interventions?. Current Alzheimer Research, 2021, 17, 781-789.	1.4	0
114	Application of Alzheimer Biomarkers in Clinical Practice. , 2014, , 27-36.		0
115	Tracking the Progression. , 2014, , 23-26.		0
116	Enhancing medical journalism from Internet Medical Society. International Journal of Case Reports and Images, 2015, 6, 537.	0.0	0
117	Learning Fuzzy Models with a SAX-based Partitioning for Simulated Seizure Recognition. Advances in Intelligent Systems and Computing, 2017, , 20-30.	0.6	0
118	Biomarcadores para el diagnÃ³stico de la Enfermedad de Alzheimer. Biomedicina, 0, , .	0.0	0